Fundraising FoxAvilar Therapeutics
Waltham, US · Founded 2020 · Massachusetts corporation · 5 known investors
Find your way into Avilar Therapeutics
Sign up to see every warm intro you have to Avilar Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avilar Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.
Founders & leadership
Board
Investors · 5
How we know: Medical Excellence Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$75.3M disclosed across 1 round · 2020
▶$75.3MraisedFeb 2023 · 5 investors · PharmaceuticalsRule 506(b)
- THERESA CAMERONDirector
- PAULINA HILLDirector
- MARTIN FREEDDirector
- STEPHANIE TOZZOExecutive Officer
- PHIL GRAHAMExecutive Officer
- MILIND DESHPANDEDirector
- DAVID NEAFUSExecutive Officer
- DANIEL GRAUExecutive Officer, Director
- ADAM MUZIKANTExecutive Officer
- JOSHUA RESNICKDirector
- Offering amount
- $75.3M
- Amount sold
- $75.3M
- First sale
- Dec 2020
- Incorporated
- Corporation, Massachusetts, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Avilar Therapeutics.
Frequently asked questions
- What does Avilar Therapeutics do?
- Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.
- Who are Avilar Therapeutics's investors?
- Avilar Therapeutics's investors include Astellas Venture Management LLC, Medical Excellence Capital, RA Capital, Sanofi Ventures, OpenSky Ventures.
- How much funding has Avilar Therapeutics raised?
- Avilar Therapeutics has disclosed $75.3M raised across 1 round.
- Where is Avilar Therapeutics headquartered?
- Avilar Therapeutics is headquartered in Waltham, US.